AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
During the July 22 morning plenary session, Stacey Hughes, AHA’s executive vice president of government relations and public policy, moderated a panel with…
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA July 15 commented to Sens. Sheldon Whitehouse, D-R.I., and Bill Cassidy, R-La., responding to a request for information based on the Pay PCPs Act,…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
Improving access to rural health care is a top priority for AHA, and its 2024 Rural Advocacy Agenda lays the groundwork to improve the system as a whole. In…
Headline
The House Appropriations Committee July 10 voted 31-25 to approve legislation that would provide $185.8 billion in funding for the departments of Labor, Health…